Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2022

Open Access 01-12-2022 | Spondyloarthropathy | Research

The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis

Authors: Meimei Cai, Wen Liu, Yuanhui Wu, Qing Zheng, Dehao Liu, Guixiu Shi

Published in: BMC Musculoskeletal Disorders | Issue 1/2022

Login to get access

Abstract

Objectives

To investigate longitudinal relationship between serum uric acid (SUA) and disease activity among Chinese males with axial spondyloarthritis (axSpA).

Methods

Two-year data from the NASA study cohort of male patients with axial spondyloarthritis were analyzed. Patients global assessment of disease activity (PtGA), BASDAI, ASDAS-CRP, BASFI, and SF-36 were used as the outcomes. The autoregressive Generalized Estimation Equation (GEE) model was used to investigate the longitudinal relationship between SUA and the above outcomes. Age and gender and symptom duration were tested as effect modifiers or confounders.

Results

In total, 102 male axSpA patients were included, 33.3% of who were hyperuricemia at baseline. Over time,serum uric acid levels associated with the global assessment of patient global assessment of disease activity (PtGA)[P=0.041, β=-2.059,95%CI(-4.032, -0.086)], SF-36: Vitality (VT) [P=0.01, β=1.751, 95%CI (0.415,3.087)], SF-36: Social Functioning (SF)[P=0.002, β= 2.968,95%CI (1.067,4.869)]). And these relationgships were independent of age, symptom duration, baseline uric acid levels, and medication use.

Conclusions

In summary, SUA levels is longitudinally related to PtGA and mental health assessment. Age, gender and symptom duration do not have an impact on the relationships.
Appendix
Available only for authorised users
Literature
1.
de Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: Consensus and controversies. Eur J Clin Investig. 2018;48(5):e12913.CrossRef
2.
Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N. Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol. 2017;13(6):359–67.PubMedCrossRef
3.
4.
5.
Kaneko K, Aoyagi Y, Fukuuchi T, Inazawa K, Yamaoka N. Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biol Pharm Bull. 2014;37(5):709–21.PubMedCrossRef
6.
Han QX, Zhang D, Zhao YL, Liu L, Li J, Zhang F, et al. Risk Factors For Hyperuricemia In Chinese Centenarians And Near-Centenarians. Clin Interv Aging. 2019;14:2239–47.PubMedPubMedCentralCrossRef
7.
Kang KY, Hong YS, Park SH, Ju JH. Low levels of serum uric Acid increase the risk of low bone mineral density in young male patients with ankylosing spondylitis. J Rheumatol. 2015;42(6):968–74.PubMedCrossRef
8.
Zhang XJ, Cui XM, Chen RY, Sun HT, Zhou JJ, Jiang LD. The analysis of clinical characteristics and disease activity in ankylosing spondylitis patients with hyperuircemia. Zhonghua Yi Xue Za Zhi. 2018;98(13):982–6.PubMed
9.
Poddubnyy D, Sieper J. Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep. 2017;19(9):55.PubMedCrossRef
10.
van der Linden S, Akkoc N, Brown MA, Robinson PC, Khan MA. The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward. Curr Rheumatol Rep. 2015;17(9):62.PubMedCrossRef
11.
12.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.PubMed
13.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24.PubMedCrossRef
14.
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281–5.PubMed
15.
Saquib N, Brunner R, Desai M, Kroenke C, Martin LW, Daviglus M, et al. Changes in physical and mental health are associated with cardiovascular disease incidence in postmenopausal women. Age Ageing. 2019;48(3):448–53.PubMedPubMedCentralCrossRef
16.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef
17.
Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids. 2009;28(2):118–49.PubMedPubMedCentralCrossRef
18.
Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75–86.PubMedCrossRef
19.
Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287–9.PubMedCrossRef
20.
Waldron JL, Ashby HL, Razavi C, Thomas OL, Chugh S, Deshpande S, et al. The effect of the systemic inflammatory response, as provoked by elective orthopaedic surgery, on serum uric acid in patients without gout: a prospective study. Rheumatology (Oxford). 2013;52(4):676–8.CrossRef
21.
Pietsch DEW, Kubler P, Robinson PC. The effect of reducing systemic inflammation on serum urate. Rheumatology (Oxford). 2020;59(10):3108–9.CrossRef
22.
Hasikova L, Pavlikova M, Hulejova H, Kozlik P, Kalikova K, Mahajan A, et al. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Rheumatol Int. 2019;39(10):1749–57.PubMedCrossRef
23.
Liu W, Zhang H, Han X, Zhang P, Mao Z. Uric acid level changes after bariatric surgery in obese subjects with type 2 diabetes mellitus. Ann Transl Med. 2019;7(14):332.PubMedPubMedCentralCrossRef
24.
Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9.PubMedCrossRef
25.
Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem. 2010;285(10):7176–86.PubMedCrossRef
26.
27.
Flögel U, Burghoff S, van Lent PL, Temme S, Galbarz L, Ding Z, et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med. 2012;4(146):146ra108.PubMedCrossRef
28.
Liu Y, Zou H, Zhao P, Sun B, Wang J, Kong Q, et al. Activation of the adenosine A2A receptor attenuates experimental autoimmune encephalomyelitis and is associated with increased intracellular calcium levels. Neuroscience. 2016;330:150–61.PubMedCrossRef
29.
Wang L, Wan H, Tang W, Ni Y, Hou X, Pan L, et al. Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. Clin Respir J. 2018;12(1):149–57.PubMedCrossRef
30.
Akhtari M, Zargar SJ, Mahmoudi M, Vojdanian M, Rezaeimanesh A, Jamshidi A. Ankylosing spondylitis monocyte-derived macrophages express increased level of A (2A) adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A (1) and A (2B) adenosine receptors. Clin Rheumatol. 2018;37(6):1589–95.PubMedCrossRef
31.
Ravani A, Vincenzi F, Bortoluzzi A, Padovan M, Pasquini S, Gessi S, et al. Role and Function of A (2A) and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis. Int J Mol Sci. 2017;18(4).
32.
Baggott JE, Morgan SL. Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism. Eur J Pharm Sci. 2007;31(2):95–101.PubMedPubMedCentralCrossRef
33.
Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A. 1999;96(11):6377–81.PubMedPubMedCentralCrossRef
34.
Rahimian R, Fakhfouri G, Daneshmand A, Mohammadi H, Bahremand A, Rasouli MR, et al. Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. Eur J Pharmacol. 2010;649(1-3):376–81.PubMedCrossRef
35.
Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001;12(12):2797–806.PubMedCrossRef
36.
Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses. 2002;58(4):297–304.PubMedCrossRef
37.
Bartoli F, Crocamo C, Mazza MG, Clerici M, Carrà G. Uric acid levels in subjects with bipolar disorder: A comparative meta-analysis. J Psychiatr Res. 2016;81:133–9.PubMedCrossRef
38.
van Calker D, Biber K, Domschke K, Serchov T. The role of adenosine receptors in mood and anxiety disorders. J Neurochem. 2019;151(1):11–27.PubMedCrossRef
Metadata
Title
The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis
Authors
Meimei Cai
Wen Liu
Yuanhui Wu
Qing Zheng
Dehao Liu
Guixiu Shi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2022
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-022-05657-3

Other articles of this Issue 1/2022

BMC Musculoskeletal Disorders 1/2022 Go to the issue

Research

Risk factors for prolonged preoperative waiting time of intertrochanteric fracture patients undergoing operative treatment

Research

A comparative study of percutaneous endoscopic interlaminar discectomy and transforaminal discectomy for L5-S1 calcified lumbar disc herniation

Research

Clinical application of modified Crain classification in the Design of Anterior Cruciate Ligament Reconstruction with remnant preservation

Research

Risk factor of postoperative incision infection after plate internal fixation of calcaneal fractures: a retrospective study

Research

The influence of diverse bone cement distribution patterns for metastatic vertebral lesions after bilateral percutaneous kyphoplasty

Research

Age- and sex-dependent differences in the morphology and composition of paraspinal muscles between subjects with and without lumbar degenerative diseases